Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes

Yuming Wang,1,2,* Yunting Zhou,2,* Xiao Zhou,2,* Xiaofei Su,2,* Xiaohua Xu,2 Huiqin Li,2 Jianhua Ma2 1Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China; 2Dep...

Full description

Bibliographic Details
Main Authors: Wang Y, Zhou Y, Zhou X, Su X, Xu X, Li H, Ma J
Format: Article
Language:English
Published: Dove Medical Press 2023-12-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
Online Access:https://www.dovepress.com/effect-of-chiglitazar-and-sitagliptin-on-bone-mineral-density-and-body-peer-reviewed-fulltext-article-DMSO
_version_ 1797373569667170304
author Wang Y
Zhou Y
Zhou X
Su X
Xu X
Li H
Ma J
author_facet Wang Y
Zhou Y
Zhou X
Su X
Xu X
Li H
Ma J
author_sort Wang Y
collection DOAJ
description Yuming Wang,1,2,* Yunting Zhou,2,* Xiao Zhou,2,* Xiaofei Su,2,* Xiaohua Xu,2 Huiqin Li,2 Jianhua Ma2 1Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China; 2Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210012, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huiqin Li; Jianhua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, Email Lihuiqin496@126.com; majianhua196503@126.comAim: To evaluate the changes in bone mineral density (BMD) and body composition in untreated patients with type 2 diabetes mellitus (T2DM) before and after chiglitazar or sitagliptin treatment.Methods: A total of 81 patients with T2DM were randomly divided to receive chiglitazar or sitagliptin treatment for 24 weeks (54 in the chiglitazar group and 27 in the sitagliptin group). We measured the spine lumbar BMD, hip BMD, fat mass (FM), fat-free mass (FFM), percent body fat (%BF), android FM, gynoid FM and skeleton muscle mass (SMM) using dual-energy X-ray absorptiometry (DEXA) and examined serum adiponectin (ADP) levels at baseline and the end of the study.Results: There were no significant changes in the BMD of the L2-4, femoral neck, trochanter or total hip as well as in the BMC after 24 weeks of treatment with chiglitazar or sitagliptin. After chiglitazar administration, the FM, gynoid FM and gynoid to total FM ratio were higher, while the android to total FM ratio and the android to gynoid FM ratio (AOI) were significantly lower. Sitagliptin intervention did not result in statistically significant differences in total fat loss, but it did cause significant decreases in %BF and AOI as well as increases in the FFM, gynoid to total FM ratio and SMM. The ADP levels had significantly negative associations with AOI in all eligible patients.Conclusion: The chiglitazar had no deleterious effects on BMD and resulted in body fat redistribution in untreated patients with T2DM.Trial Registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02173457).Keywords: type 2 diabetes mellitus, chiglitazar, PPAR, bone mineral density, body composition
first_indexed 2024-03-08T18:51:23Z
format Article
id doaj.art-cbfe7a243848433e82c6300a4eb60081
institution Directory Open Access Journal
issn 1178-7007
language English
last_indexed 2024-03-08T18:51:23Z
publishDate 2023-12-01
publisher Dove Medical Press
record_format Article
series Diabetes, Metabolic Syndrome and Obesity
spelling doaj.art-cbfe7a243848433e82c6300a4eb600812023-12-28T18:07:22ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072023-12-01Volume 164205421489328Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 DiabetesWang YZhou YZhou XSu XXu XLi HMa JYuming Wang,1,2,* Yunting Zhou,2,* Xiao Zhou,2,* Xiaofei Su,2,* Xiaohua Xu,2 Huiqin Li,2 Jianhua Ma2 1Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China; 2Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210012, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huiqin Li; Jianhua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, Email Lihuiqin496@126.com; majianhua196503@126.comAim: To evaluate the changes in bone mineral density (BMD) and body composition in untreated patients with type 2 diabetes mellitus (T2DM) before and after chiglitazar or sitagliptin treatment.Methods: A total of 81 patients with T2DM were randomly divided to receive chiglitazar or sitagliptin treatment for 24 weeks (54 in the chiglitazar group and 27 in the sitagliptin group). We measured the spine lumbar BMD, hip BMD, fat mass (FM), fat-free mass (FFM), percent body fat (%BF), android FM, gynoid FM and skeleton muscle mass (SMM) using dual-energy X-ray absorptiometry (DEXA) and examined serum adiponectin (ADP) levels at baseline and the end of the study.Results: There were no significant changes in the BMD of the L2-4, femoral neck, trochanter or total hip as well as in the BMC after 24 weeks of treatment with chiglitazar or sitagliptin. After chiglitazar administration, the FM, gynoid FM and gynoid to total FM ratio were higher, while the android to total FM ratio and the android to gynoid FM ratio (AOI) were significantly lower. Sitagliptin intervention did not result in statistically significant differences in total fat loss, but it did cause significant decreases in %BF and AOI as well as increases in the FFM, gynoid to total FM ratio and SMM. The ADP levels had significantly negative associations with AOI in all eligible patients.Conclusion: The chiglitazar had no deleterious effects on BMD and resulted in body fat redistribution in untreated patients with T2DM.Trial Registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02173457).Keywords: type 2 diabetes mellitus, chiglitazar, PPAR, bone mineral density, body compositionhttps://www.dovepress.com/effect-of-chiglitazar-and-sitagliptin-on-bone-mineral-density-and-body-peer-reviewed-fulltext-article-DMSOtype 2 diabetes mellituschiglitazarpparbone mineral densitybody composition.
spellingShingle Wang Y
Zhou Y
Zhou X
Su X
Xu X
Li H
Ma J
Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
Diabetes, Metabolic Syndrome and Obesity
type 2 diabetes mellitus
chiglitazar
ppar
bone mineral density
body composition.
title Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
title_full Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
title_fullStr Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
title_full_unstemmed Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
title_short Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes
title_sort effect of chiglitazar and sitagliptin on bone mineral density and body composition in untreated patients with type 2 diabetes
topic type 2 diabetes mellitus
chiglitazar
ppar
bone mineral density
body composition.
url https://www.dovepress.com/effect-of-chiglitazar-and-sitagliptin-on-bone-mineral-density-and-body-peer-reviewed-fulltext-article-DMSO
work_keys_str_mv AT wangy effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT zhouy effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT zhoux effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT sux effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT xux effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT lih effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes
AT maj effectofchiglitazarandsitagliptinonbonemineraldensityandbodycompositioninuntreatedpatientswithtype2diabetes